Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.40 |
| ▸ | OXTR | P30559 | 4/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 5/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1099319 | 0.87 | F2 (0.37) | F2ALOX5APFEN1HDAC1HDAC6 | |
| SCHEMBL6040385 | 0.87 | TP53 (0.35) | F2ALOX5APFEN1HDAC1HDAC6 | |
| SCHEMBL1097728 | 0.84 | MLYCD (0.39) | F2OXTRALOX5APFEN1HDAC1 | |
| SCHEMBL3822535 | 0.83 | OXTR (0.43) | OXTRAVPR1AAVPR2MTORHDAC1 | |
| SCHEMBL1794562 | 0.81 | F2 (0.39) | F2OXTRAVPR1AAVPR2HDAC1 | |
| SCHEMBL18291311 | 0.79 | HDAC1 (0.34) | F2ALOX5APFEN1HDAC1HDAC6 | |
| SCHEMBL1009548 | 0.79 | F2 (0.37) | F2OXTRAVPR1AAVPR2KDM4E | |
| SCHEMBL22544386 | 0.78 | PIK3CA (0.38) | MTORALOX5APFEN1PIK3CA | |
| SCHEMBL18291249 | 0.78 | GABRP (0.40) | F2MTORHDAC1HDAC6GABRP | |
| SCHEMBL2664537 | 0.78 | HCAR3 (0.45) | F2KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| EP-1529530-B3 | Compounds affecting glucokinase | ASTRAZENECA AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| EP-1669069-A1 | Compounds effecting glukokinase | AstraZeneca AB (SE) | 2006-06-14 | — | — | EP | disclosed |
| EP-1661569-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661567-A1 | Compounds effecting Glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661563-A1 | Compound effecting Glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661568-A1 | Compounds effecting Glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1568367-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1529530-A1 | Compounds affecting glucokinase | AstraZeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20050080106-A1 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2005-04-14 | — | — | US | disclosed |
| EP-1420784-A1 | COMPOUNDS EFFECTING GLUCOKINASE | Astrazeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003015774-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080106-A1 | Compounds effecting glucokinase | GCKR, GCK, SLC5A2 | F2 1217/4885OXTR 2623/4885AVPR1A 983/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | F2 1217/4885OXTR 2623/4885AVPR1A 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.